Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 176Colorectal Neoplasms 153Rectal Neoplasms 122Stomach Neoplasms 112Pancreatic Neoplasms 60Neoplasm Metastasis 60Colonic Neoplasms 42Triple Negative Breast Neoplasms 34Neoplasms 29Esophageal Neoplasms 28Cholangiocarcinoma 18Gallbladder Neoplasms 17Biliary Tract Neoplasms 17Nasopharyngeal Carcinoma 16Carcinoma, Hepatocellular 16Adenocarcinoma 16Locally Advanced Rectal Cancer 15Squamous Cell Carcinoma of Head and Neck 10Head and Neck Neoplasms 10Esophageal Squamous Cell Carcinoma 10Brain Neoplasms 10Bile Duct Neoplasms 10Adenocarcinoma Of Esophagus 10Liver Neoplasms 9Gastrointestinal Neoplasms 9Breast Neoplasms, Male 9Neuroendocrine Tumors 7Colorectal Cancer Metastatic 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6

Interventions

Paclitaxel 2Nivolumab 2Bevacizumab 2liposomal doxorubicin 1dostarlimab 1Sunitinib 1Radiotherapy 1Ipilimumab 1Gemcitabine 1Erlotinib Hydrochloride 1Doxorubicin 1Celecoxib 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma, Clear Cell × Capecitabine × Clear all
NCT00226798 2006-01-04

Immunochemotherapy for Metastatic Renal Cell Carcinoma

Rambam Health Care Campus

Phase 2 Unknown
45 enrolled

Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡